孟鲁司特钠治疗慢性阻塞性肺疾病急性加重期患者疗效观察  

Efficacy of Montelukast Sodium for Chronic Obstructive Pulmonary Disease at Acute Exacerbation Stage

作　　者：郑姣妮[1] 刘玲[1] 冯兵[1] 刘颖宏[2] 

机构地区：[1]重庆市急救医疗中心药剂科,重庆400014 [2]重庆市急救医疗中心呼吸科,重庆400014

出　　处：《中国医院用药评价与分析》2014年第12期1090-1092,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨孟鲁司特钠治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)急性加重期患者的疗效。方法:将106例COPD急性加重期患者以抽签法随机分为治疗组和对照组各53例,对照组采用常规治疗,治疗组患者在对照组基础上加服孟鲁司特钠片10 mg,每晚睡前服用,疗程为14 d。对患者治疗前后的呼吸困难评分、血气分析、肺功能各指标进行测定和分析。结果:治疗14 d后,2组患者呼吸困难评分、血气分析、肺功能各指标均较治疗前改善,差异有统计学意义(P<0.05);治疗组患者治疗后各指标较对照组改善更显著,2组差异有统计学意义(P<0.05);治疗组患者未见明显不良反应。结论:孟鲁司特钠治疗COPD急性加重期安全、有效,可广泛应用于COPD的临床治疗中。OBJECTIVE：To evaluate the clinical efficacy of Montelukast for chronic obstructive pulmonary disease （ COPD ） at exacerbation stage. METHODS：80 COPD patients at exacerbation stage were randomly divided into treatment group（n=53）and control group（n=53）. The control group was given conventional treatment, while the treatment group was given add-on montelukast tablets（ Singulair,10 mg） orally quaque nocte for 14 days. The MMRC dyspnea score, blood gas analysis and pulmonary function were measured and analyzed before and after treatment. RESULTS：After treatment of14 days, the MMRC dyspnea score, blood gas analysis and pulmonary function in both groups were improved compared with before treatment（P〈0.05）and the differences between the two groups were also significant（ P 〈 0.05 ） . No apparent adverse drug reactions were noted in the treatment group. CONCLUSIONS：Montelukast sodium was proved to be safe and effective for COPD.

关 键 词：孟鲁司特钠 慢性阻塞性肺疾病 疗效观察 

分 类 号：R974[医药卫生—药品]